Pasar al contenido principal

CELULAS VASCULARES LISAS, TRANSPORTE REVERSO DE COLESTEROL Y MIRNAS: MECANISMOS PATOFISIOLOGICOS Y NUEVAS DIANAS PARA PREVENIR LA ENFERMEDAD CARDIOVASCULAR

PID2022-137186OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions

  • Vizarraga, David|||0000-0002-4478-0155
  • Marcos, Marina
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Martín Sánchez, Jesús|||0000-0003-4250-4824
  • Santos, David|||0000-0003-1157-4969
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Soto, Begoña|||0000-0002-5965-1292
  • Guerra, Pablo|||0000-0002-0154-3862
  • Wu, Wanlu
  • Serrano, Luis|||0000-0002-5276-1392
  • Piñol Ribas, Jaume|||0000-0002-9055-8934
  • Fita, Ignacio|||0000-0002-7521-2679
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Velasco Reniu, Lorena|||0009-0002-6326-4532
  • Pareja, Félix
  • Collantes, María
  • Rodriguez Arce, Irene
Mycoplasma pneumoniae (MPN) i s a bacterial pathogen that primarily causes atypical pneumonia. It cannot synthesize certain essential lipids and therefore relies on the host for their acquisition to survive. MPN has been detected in increased amounts within ruptured atherosclerotic plaques. In this work, we show that the protein P116 facilitates cholesterol acquisition from LDL, HDL and various cell types. Targeting P116's C-terminal domain with a monoclonal antibody inhibits cholesterol acquisition and bacterial growth in vitro. Phase contrast epifluorescence microscopy of human arteries reveals that this antibody blocks MPN binding to atherosclerotic lesions ex vivo. Additionally, an MPN chassis injected into hyperlipidemic female mice localizes to the liver and atherosclerotic plaques. Here, we report that P116 plays a role in extracting essential lipids from lipoproteins and host cells and regulates MPN localization to atheromatous plaques. The study highlights MPN 's potential as a tool for targeting atherosclerotic lesions and fatty liver. In this work, the authors show that the essential Mycoplasma pneumoniae protein P116 enables cholesterol acquisition from lipoproteins and various cell types. An antibody against its C-terminal domain inhibits lipid acquisition, growth, and plaque binding, linking M. pneumoniae to atherosclerotic lipid-rich tissue.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions

  • Vizarraga, David
  • Marcos, Marina
  • Rotllan, Noemí
  • Martín, Jesús
  • Santos, David
  • Camacho, Mercedes
  • Soto, Begoña
  • Velasco-Reniu, Lorena
  • Guerra, Pablo
  • Pareja, Félix
  • Collantes, María
  • Wu, Wanlu
  • Rodriguez-Arce, Irene
  • Serrano Pubull, Luis, 1982-
  • Piñol, Jaume
  • Fita, Ignacio
  • Escolà-Gil, Joan Carles
Mycoplasma pneumoniae (MPN) is a bacterial pathogen that primarily causes atypical pneumonia. It cannot synthesize certain essential lipids and therefore relies on the host for their acquisition to survive. MPN has been detected in increased amounts within ruptured atherosclerotic plaques. In this work, we show that the protein P116 facilitates cholesterol acquisition from LDL, HDL and various cell types. Targeting P116's C-terminal domain with a monoclonal antibody inhibits cholesterol acquisition and bacterial growth in vitro. Phase contrast epifluorescence microscopy of human arteries reveals that this antibody blocks MPN binding to atherosclerotic lesions ex vivo. Additionally, an MPN chassis injected into hyperlipidemic female mice localizes to the liver and atherosclerotic plaques. Here, we report that P116 plays a role in extracting essential lipids from lipoproteins and host cells and regulates MPN localization to atheromatous plaques. The study highlights MPN's potential as a tool for targeting atherosclerotic lesions and fatty liver., This work was partly funded by the Instituto de Salud Carlos III and FEDER "Una manera de hacer Europa" grant PI2300232 (to J.E.-G.). N.R. was funded by Agencia Estatal de Investigación (AEI/10.13039/501100011033 and CNS2023-144119) within the Subprograma Ramón y Cajal (RYC-201722879) and by MICINN-Spain grant PID2022-137186OB-I00. CIBERDEM is an Instituto de Salud Carlos III project. I.F. and J.P. were funded by MICINN-Spain grant PID2021-125632OB-C21 and PID2021-125632OB-C22. The authors acknowledge funding from Project, IU16-014045 (CRYO-TEM) from Generalitat de Catalunya, and by "ERDF A way of making Europe", by the European Union.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, Maria Teresa
  • Martínez, Andrea
  • Claudi, Lene
  • García, E.
  • Benitez-Amaro, Aleyda
  • Polishchuk, Anna
  • Piñero, J.
  • Vilades, David
  • Guerra Ramos, José María
  • Sanz, F.
  • Rotllan, Noemi
  • Escolà-Gil, Joan Carles
  • Llorente-Cortés, Vicenta
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future., The economic support to develop this project was received from FIS PI21/01523 (to VLl-C) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs, and Fundación BBVA Ayudas a equipos de investigación 2019. Aleyda Benitez Amaro (ABA) is a postdoctoral fellow (FI19/00205) that was granted by the Programme Contratos predoctorales de formación de investigación en salud_from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. The RIFS methodology required to analyze mitochondrial respiration in frozen cardiac samples was developed thanks to the AYUDAS PARA LA MOVILIDAD DE PERSONAL INVESTIGADOR CONTRATADO EN EL MARCO DE LA AES (M-AES) del ISCIII granted by ABA (MV21/00060). Our group is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to VLl-C), and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/016 to JC-EG and NR), projects run by the Instituto de Salud Carlos III. Our group also participates in Redes de investigación (Enfermedades Metabóloicas y Cáncer RED2018-102799-T), a project run by MINECO. We belong to a group recognized by Generalitat de Catalunya (2021 SGR 00834). This work was also funded by Ministerio de Ciencia, Innovación y Universidades (PID2022-137186OB-100), as well as from the Agencia Estatal de Investigación (AEI/10.13039/501100011033) within the Subprograma Ramón y Cajal (RYC-201722879) to NR. The IR SANT PAU is a centre of CERCA Programme/Generalitat de Catalunya, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Restoring cholesterol efflux in vascular smooth muscle cells transitioning into foam cells through Liver X receptor activation

  • Borràs, Carla
  • Rotllan, Noemí
  • Griñán, Raquel
  • Santos, David
  • Solé, Arnau
  • Dong, Chen
  • Zhao, Qi
  • Llorente-Cortés, Vicenta
  • Mourín, Marta
  • Soto, Begoña
  • Camacho, Mercedes
  • Tondo, Mireia
  • Canyelles, Marina
  • Blanco-Vaca, Francisco
  • Escolà-Gil, Joan Carles
Macrophage foam cells derived from vascular smooth muscle cells (VSMCs) account for 30–70 % of foam cells in atherosclerotic lesions. Liver X receptor (LXR) agonists promote high-density lipoprotein (HDL)-mediated cholesterol efflux from macrophages. This study aimed to investigate the effects of LXR activation on the reverse cholesterol transport (RCT) rate from VSMCs to feces in vivo. Both human and mouse VSMCs exhibited similar levels of cholesterol efflux when exposed to serum and HDL. However, cholesterol efflux was significantly reduced following methyl-β-cyclodextrin (MBD)-cholesterol loading, while treatment with the LXR agonist T090137 markedly enhanced efflux. Radiolabeled foam-like VSMCs injected intraperitoneally into mice exhibited impaired cholesterol transfer to serum, HDL, and feces compared to non-lipid-laden VSMCs. Pre-treatment with the LXR agonist increased radiolabeled cholesterol levels in serum and HDL and doubled its fecal excretion. Furthermore, LXR activation restored RCT from MBD-cholesterol-loaded VSMCs to feces, reaching levels comparable to those of non-lipid-laden cells. Treatment with an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor fully restored RCT rates in foam-like VSMCs, and the combination of the ACAT inhibitor and the LXR agonist further enhanced RCT. These findings indicate that HDL-mediated cholesterol efflux is significantly impaired during the transition of VSMCs into foam cells. Pharmacological activation of LXR enhances RCT from VSMCs to feces in vivo and restores the impaired RCT from transitioning VSMCs. The combination of LXR agonists and ACAT inhibitors holds promise as a synergistic therapeutic approach to restoring cholesterol homeostasis in lipid-laden VSMCs, offering potential strategies to mitigate atherosclerosis., This work was partly funded by the Instituto de Salud Carlos III and FEDER "Una manera de hacer Europa" grants PI2100140 (to F.B-V and M.T), PI2300232 (to M.C and J.E-G), JR22/00003 (to M.C.), PI2101523 (to V.Ll-C.) and the Ministerio de Ciencia, Innovación y Universidades, grants PID2022–137186OB-I00 and CNS2023–144119 (to N.R.). C.B. was funded with a Formación de Profesorado Universitario grant FPU20/07440 from Ministerio de Universidades. N.R was funded by Agencia Estatal de Investigación (AEI/10.13039/501100011033) within the Subprograma Ramón y Cajal (RYC-201722879). Q.Z. and C.D. were supported by the State Scholarship Fund from the China Scholarship Council (Grant Nos. 202406170068 and 202408370068, respectively). CIBERDEM and CIBERCV are Instituto de Salud Carlos III projects. All authors declare that they have no relationships relevant to the contents of this paper to disclose and have approved the final version of the article., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions

  • Vizarraga, David
  • Marcos, Marina
  • Rotllan, Noemi
  • Martín, Jesús
  • Santos, David
  • Camacho, Mercedes
  • Soto, Begoña
  • Velasco-Reniu, Lorena
  • Guerra, Pablo
  • Pareja, Félix
  • Collantes, María
  • Wu, Wanlu
  • Rodríguez-Arce, Irene
  • Serrano, Luis
  • Piñol, Jaume
  • Fita, Ignacio
  • Escolà-Gil, Joan Carles
Mycoplasma pneumoniae (MPN) is a bacterial pathogen that primarily causes atypical pneumonia. It cannot synthesize certain essential lipids and therefore relies on the host for their acquisition to survive. MPN has been detected in increased amounts within ruptured atherosclerotic plaques. In this work, we show that the protein P116 facilitates cholesterol acquisition from LDL, HDL and various cell types. Targeting P116’s C-terminal domain with a monoclonal antibody inhibits cholesterol acquisition and bacterial growth in vitro. Phase contrast epifluorescence microscopy of human arteries reveals that this antibody blocks MPN binding to atherosclerotic lesions ex vivo. Additionally, an MPN chassis injected into hyperlipidemic female mice localizes to the liver and atherosclerotic plaques. Here, we report that P116 plays a role in extracting essential lipids from lipoproteins and host cells and regulates MPN localization to atheromatous plaques. The study highlights MPN’s potential as a tool for targeting atherosclerotic lesions and fatty liver., This work was partly funded by the Instituto de Salud Carlos III and FEDER “Una manera de hacer Europa” grant PI2300232 (to J.E.-G.). N.R. was funded by Agencia Estatal de Investigación (AEI/10.13039/501100011033 and CNS2023-144119) within the Subprograma Ramón y Cajal (RYC-201722879) and by MICINN-Spain grant PID2022-137186OB-I00. CIBERDEM is an Instituto de Salud Carlos III project. I.F. and J.P. were funded by MICINN-Spain grant PID2021-125632OB-C21 and PID2021-125632OB-C22. The authors acknowledge funding from Project, IU16-014045 (CRYO-TEM) from Generalitat de Catalunya, and by “ERDF A way of making Europe”, by the European Union., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions

  • Vizarraga, David
  • Marcos, Marina
  • Rotllan, Noemí
  • Martín, Jesús
  • Santos, David
  • Camacho, Mercedes
  • Soto, Begoña
  • Velasco-Reniu, Lorena
  • Guerra, Pablo
  • Pareja, Félix
  • Collantes, María
  • Wu, Wanlu
  • Rodriguez-Arce, Irene
  • Serrano Pubull, Luis, 1982-
  • Piñol, Jaume
  • Fita, Ignacio
  • Escolà-Gil, Joan Carles
Mycoplasma pneumoniae (MPN) is a bacterial pathogen that primarily causes atypical pneumonia. It cannot synthesize certain essential lipids and therefore relies on the host for their acquisition to survive. MPN has been detected in increased amounts within ruptured atherosclerotic plaques. In this work, we show that the protein P116 facilitates cholesterol acquisition from LDL, HDL and various cell types. Targeting P116's C-terminal domain with a monoclonal antibody inhibits cholesterol acquisition and bacterial growth in vitro. Phase contrast epifluorescence microscopy of human arteries reveals that this antibody blocks MPN binding to atherosclerotic lesions ex vivo. Additionally, an MPN chassis injected into hyperlipidemic female mice localizes to the liver and atherosclerotic plaques. Here, we report that P116 plays a role in extracting essential lipids from lipoproteins and host cells and regulates MPN localization to atheromatous plaques. The study highlights MPN's potential as a tool for targeting atherosclerotic lesions and fatty liver., This work was partly funded by the Instituto de Salud Carlos III and FEDER "Una manera de hacer Europa" grant PI2300232 (to J.E.-G.). N.R. was funded by Agencia Estatal de Investigación (AEI/10.13039/501100011033 and CNS2023-144119) within the Subprograma Ramón y Cajal (RYC-201722879) and by MICINN-Spain grant PID2022-137186OB-I00. CIBERDEM is an Instituto de Salud Carlos III project. I.F. and J.P. were funded by MICINN-Spain grant PID2021-125632OB-C21 and PID2021-125632OB-C22. The authors acknowledge funding from Project, IU16-014045 (CRYO-TEM) from Generalitat de Catalunya, and by "ERDF A way of making Europe", by the European Union.